^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMC002

    i
    Other names: IMC002, IMC 002, IMC-002, 3D197
    Associations

    News

    Trials
    Company:
    3DMed, Immuneoncia Therap
    Drug class:
    CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Model-Informed Optimal Dosing of Anti-CD47 Antibody Using Target-Mediated Drug Disposition Model. (PubMed, Clin Transl Sci)
    The ideal regimen of 20 mg/kg every 3 weeks ensured that the mean plasma concentration remained above the MEC throughout the dosing interval. Our study developed a robust TMDD PK model for IMC-002, which provides the rationale for a dose regimen in a phase 1b study.
    Journal
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    IMC002
    6ms
    A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy (clinicaltrials.gov)
    P1, N=62, Recruiting, ImmuneOncia Therapeutics Inc. | Trial completion date: Dec 2026 --> Aug 2029 | Trial primary completion date: Jun 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • IMC002
    over1year
    A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (clinicaltrials.gov)
    P1, N=12, Completed, ImmuneOncia Therapeutics Inc. | Recruiting --> Completed | N=24 --> 12
    Trial completion • Enrollment change • Metastases
    |
    IMC002
    over1year
    A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy (clinicaltrials.gov)
    P1, N=49, Recruiting, ImmuneOncia Therapeutics Inc. | N=24 --> 49 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jul 2024 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    IMC002
    over5years
    [VIRTUAL] A PRECLINICAL STUDY OF IMC-002, A FULLY HUMAN THERAPEUTIC ANTIBODY SAFELY TARGETING CD47 IN CANCER (EHA 2020)
    The first-in-human (FIH) study of IMC-002 is planned to be initiated during the 1st half of 2020. The purpose of the study is to assess the safety and tolerability of IMC-002 and determine the recommended Phase 2 dose (RP2D) of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas.
    Preclinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD14 (CD14 Molecule)
    |
    IMC002